Primary gastrointestinal diffuse large B-cell lymphoma: A prospective study from South India

Abstract

Background: Gastrointestinal tract (GIT) is the most common extranodal site for non-Hodgkin's lymphoma (NHL) and constitutes about 10%-15% of all NHL. This was a prospective study to evaluate the epidemiological, clinicopathological characteristics, and treatment outcome of primary GIT diffuse large B-cell lymphoma (PGIL). Materials and Methods: Newly diagnosed patients of PGIL with DLBCL histology were eligible. Lugano staging system was used. All patients were treated with prephase treatment (1 mg vincristine and 100 mg prednisolone) followed by CHOP-based chemotherapy (with or without rituximab) as definitive treatment. Results: A total of 21 patients of PGIL were diagnosed. The median age was 46 years (range: 27–69 years) with male:female ratio of 2:1. Dull aching abdominal pain was the most common presenting complaint. Stomach was the most common site involved (52.4%, n = 11) followed by the colon (23.8%, n = 5). The estimated median survival in patients with Stage IV disease was significantly lower as compared to patients with localized disease (Stage I and II) (6.23 months vs. 23.4 months; P = 0.04). Patients, who did not achieve complete response (CR), had 15.5 times higher risk of death, as compared to those who achieved CR (P = 0.01). Conclusions: Stomach was the most common site for PGIL. Localized disease and CR after first-line chemotherapy were associated with better survival. A higher cost of rituximab was the prohibitive factor for cure in these patients.

Key words

Diffuse large B-cell lymphoma - diffuse large B-cell lymphoma colon - diffuse large B-cell lymphoma stomach - gastrointestinal lymphoma

• References

• 1 d'Amore F, Brincker H, Grønbaek K, Thorling K, Pedersen M, Jensen MK, et al. Non-Hodgkin's lymphoma of the gastrointestinal tract: A population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish lymphoma study group. J Clin Oncol 1994;12:1673-84.
• 2 Bautista-Quach MA, Ake CD, Chen M, Wang J. Gastrointestinal lymphomas: Morphology, immunophenotype and molecular features. J Gastrointest Oncol 2012;3:209-25.
• 3 Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol 2011;17:697-707.
• 4 Arora N, Manipadam MT, Pulimood A, Ramakrishna BS, Chacko A, Kurian SS, et al. Gastrointestinal lymphomas: Pattern of distribution and histological subtypes: 10 years experience in a tertiary centre in South India. Indian J Pathol Microbiol 2011;54:712-9.
• 5 Dawson IM, Cornes JS, Morson BC. Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg 1961;49:80-9.
• 6 Avilés A, Díaz-Maqueo JC, de la Torre A, Rodriguez L, Guzmán R, Talavera A, et al. Is surgery necessary in the treatment of primary gastric non-Hodgkin lymphoma? Leuk Lymphoma 1991;5:365-9.
• 7 Li Q, Li W, Wang L, Wang W, Niu S, Bi X, et al. Consolidation radiotherapy in stage IE- IIE, non-bulky primary gastric diffuse large B-cell lymphoma with post-chemotherapy complete remission. PLoS One 2015;10:e0133469.
• 8 Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
• 9 Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4^th ed. Lyon: IARC; 2017.
• 10 Rohatiner A, d'Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994;5:397-400.
• 11 Lakshmaiah KC, Asati V, Babu K G, D Lokanath et al. Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma. Eur J Haematol. 2018;100:644–648. Available from: https://doi.org/10.1111/ejh.13068. [Last accessed on 2018 Jul 07].
• 12 Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
• 13 Gurney KA, Cartwright RA, Gilman EA. Descriptive epidemiology of gastrointestinal non-Hodgkin's lymphoma in a population-based registry. Br J Cancer 1999;79:1929-34.
• 14 Gou HF, Zang J, Jiang M, Yang Y, Cao D, Chen XC, et al. Clinical prognostic analysis of 116 patients with primary intestinal non-Hodgkin lymphoma. Med Oncol 2012;29:227-34.
• 15 Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, et al. Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German multicenter study GIT NHL 01/92. J Clin Oncol 2001;19:3861-73.
• 16 Shawky H, Tawfik H. Primary gastrointestinal non-Hodgkin's lymphoma: A Retrospective study with emphasis on prognostic factors and treatment outcome. J Egypt Natl Canc Inst 2008;20:330-41.
• 17 Avilés A, Nambo MJ, Neri N, Huerta-Guzmán J, Cuadra I, Alvarado I, et al. The role of surgery in primary gastric lymphoma: Results of a controlled clinical trial. Ann Surg 2004;240:44-50.
• 18 Li X, Shen W, Cao J, Wang J, Chen F, Wang C, et al. Treatment of gastrointestinal diffuse large B cell lymphoma in China: A 10-year retrospective study of 114 cases. Ann Hematol 2012;91:1721-9.